Lung cancer trials in Japan

In Japan 135 Also abroad 2747

135 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Where
Fukushima, Kitakyushu, Yamagata
Age
18 years and over
People
876 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Gifu, Hiroshima, Hyōgo, Ōita
Age
18 years and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
Phase 3Taking people
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Where
Akashi, Bunkyo-ku, Fukuoka, Hirakata, Hiroshima, Nagaizumi-cho,Sunto-gun, Natori-shi, Niigata, Sakai, Sapporo, Tokyo, Yokohama
Age
18 years and over
People
356 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566052 · EU 2025-524079-22-00
No phaseNot yet taking people in Japan
Real-world Outcome of Zongertinib in Japan (J-HERZ)
Where
Tokyo
Age
18 years and over
People
300
Run by
Boehringer Ingelheim
See details and how to joinNCT07926308
Phase 1/2Taking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Kanagawa, Okayama, Osaka, Shizuoka, Tokyo, Wakayama
Age
12 years and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
Phase 3Taking people
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Where
Bunkyo-ku, Chiba, Fukuoka, Fukuyama-shi, Hirakata-shi, Hirosaki-shi, Kanazawa, Kashiwa-shi, Kawasaki-shi, Kitakyushu-shi, Kobe, Koto-ku, Kurume-shi, Kyoto, Matsuyama, Nagoya, Natori-shi, Niigata, Okayama, Osaka, Sakai-shi, Sakai-Shi, Sapporo, Sendai, Shimotsuga-gun, Sunto-gun, Takarazuka-shi, Toon-shi, Ube-shi, Wakayama, Yokohama, Yonago-shi
Age
18 years to 100 years
People
750 worldwide
Run by
Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00
Phase 3Taking people
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Where
Akashi, Chuo Ku, Hidaka, Hirakata-shi, Kanazawa, Kashihara-shi, Kashiwa-shi, Koto-Ku, Kyoto, Matsuyama, Nagaizumi-chō, Nagoya, Niigata, Osakasayama-Shi, Sagamihara, Sapporo, Sendai, Toyoake-shi, Wakayama, Yokohama
Age
18 years and over
People
590 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00
Phase 1/2Taking people
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Where
Chiba, Osaka, Tokyo, Wakayama
Age
18 years and over
People
320 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Aichi, Fukuoka, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Miyagi, Niigata, Okayama, Osaka, Sendai, Shizuoka, Tokyo, Wakayama
Age
18 years and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Akashi, Beppu-shi, Bunkyo-ku, Fukuoka, Kiyose, Kochi, Kure, Kurume, Kyoto, Nagaizumi-chō, Okayama, Ōmura, Osaka, Sakai, Sendai, Suita, Tsu
Age
18 years and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
Phase 3Taking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Bunkyo Ku, Fukuoka, Hamamatsu, Hidaka, Hirakata, Kobe, Nagoya, Nishinomiya, Okayama, Sagamihara, Sakai, Sendai, Yokohama
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
Phase 1/2Taking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Akashi, Fukushima, Hidaka, Koto, Nagaizumi-chō, Ōta, Sapporo, Shinjuku-ku, Yamagata
Age
18 years and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
Phase 3Taking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Asahikawa, Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kasama, Kashiwa, Kobe, Kōtō City, Kyoto, Matsuyama, Nagaizumi-cho,Sunto-gun, Nagasaki, Nagoya, Natori, Niigata, Okayama, Sakai, Sapporo, Ube, Utsunomiya, Wakayama, Yokohama, Yonago
Age
18 years and over
People
1,264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Shizuoka, Tokyo
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Bunkyo-ku, Fukuoka, Himeji, Hirakata, Kashiwa, Kitaadachi, Kobe, Nagoya, Niigata, Osaka, Sagamihara, Sakai, Sapporo, Sendai, Ube, Yonago
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 1/2Taking people
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Where
Kashiwa, Osakasayama-Shi, Tsukiji
Age
18 years and over
People
675 worldwide
Run by
BlossomHill Therapeutics
See details and how to joinNCT06706076
Phase 3Taking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kashiwa, Kobe, Kōtō City, Kyoto, Nagaizumi-cho,Sunto-gun, Nagoya, Natori, Niigata, Sakai, Sapporo, Wakayama, Yokohama, Yonago
Age
18 years and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Chuo Ku
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
Phase 2Taking people
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Where
Himeji, Matsusaka, Niigata, Shizuoka, Tokyo, Wakayama
Age
18 years and over
People
520 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Bunkyo, Fukuoka, Himeji, Hirakata, Hirosaki, Kashiwa, Kawasaki, Koto, Kumamoto, Kurume, Matsusaka, Matsuyama, Niigata, Osaka, Ōta, Ōta-ku, Sendai, Shimotsugagun, Shinjuku, Shiwa-gun, Suntogun, Takatsuki, Toyoake, Ube, Ureshino, Yokohama
Age
18 years and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
Phase 2Taking people
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Where
Chūō, Kyoto, Nagoya, Sagamihara, Saitama, Sakai, Tokyo, Yokohama
Age
18 years and over
People
240 worldwide
Run by
Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00
Phase 1Taking people
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Where
Kashiwa
Age
18 years and over
People
156 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07660055
Phase 2/3Taking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Ageo, Akashi, Aomori, Bunkyō City, Chūōku, Funabashi, Himeji, Hiroshima, Iizuka, Iwakuni, Kanagawa, Kanazawa, Kumamoto, Kurashiki, Kurume, Matsusaka, Matsuyama, Meguro City, Mibu, Morioka, Nagaizumi-chō, Nagasaki, Nagoya, Niigata, Nishinomiya, Osaka, Saitama, Sakai, Sapporo, Sendai, Shibukawa, Toyama, Wakayama, Yokohama
Age
18 years and over
People
1,580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
Phase 1Taking people
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
Where
Chūōku
Age
18 years and over
People
77 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07166601